Diagnosing hereditary colorectal cancer

Clinical Colorectal Cancer

Volumn 9, Issue 4, 2010, Pages 205-211

  Gallagher, David J ^a   Smith, James D ^b   Offit, Kenneth ^a   Stadler, Zsofia K ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY HOSPITAL LIMERICK   (Ireland)

Author keywords

Familial adenomatous polyposis; Lynch syndrome; MMR; Turcot syndrome

Indexed keywords

ADENOMATOUS POLYP; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER GENETICS; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; DIFFERENTIAL DIAGNOSIS; GENETIC COUNSELING; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; HAMARTOMATOUS POLYPOSIS; HEREDITARY COLORECTAL CANCER; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HIGH RISK PATIENT; HIGH THROUGHPUT SCREENING; HUMAN; ISCHEMIC PRECONDITIONING; POLYPOSIS; PRACTICE GUIDELINE; REVIEW; RISK ASSESSMENT;

EID: 77957767335     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2010.n.030     Document Type: Review

References (113)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009; 59:225-49.
2. Samowitz WS, Curtin K, Lin HH, et al. The colon cancer burden of genetically defined hereditary nonpolyposis colon cancer. Gastroenterology 2001; 121:830-8.
3. Papaemmanuil E, Carvajal-Carmona L, Sellick GS, et al. Deciphering the genetics of hereditary non-syndromic colorectal cancer. Eur J Hum Genet 2008; 16:1477-86.
4. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J Clin Oncol 2003; 21:2397-406.
5. Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda Guidelines for heredi-tary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instabil-ity. J Natl Cancer Inst 2004; 96:261-8.
6. Hampel H, Frankel WL, Martin E, et al. Screening for the Lynch syndrome (he-reditary nonpolyposis colorectal cancer). N Engl J Med 2005; 352:1851-60.
7. Colorectal cancer screening. National Comprehensive Care Network Clinical Prac-tice Guidelines in Oncology-v.1.2010. National Comprehensive Care Network [Web site]. Available at: http://www.nccn.org/professionals/physician-gls/PDF/ colorectal-screening.pdf Accessed: September 1, 2010.
8. Jass JR. Role of the pathologist in the diagnosis of hereditary non-polyposis colorectal cancer. Dis Markers 2004; 20:215-24.
9. Boland CR. Decoding hereditary colorectal cancer. N Engl J Med 2006; 354:2815-7.
10. Menko FH, Kaspers GL, Meijer GA, et al. A homozygous MSH6 mutation in a child with cafe-au-lait spots, oligodendroglioma and rectal cancer. Fam Cancer 2004; 3:123-7.
11. Nakagawa H, Lockman JC, Frankel WL, et al. Mismatch repair gene PMS2: disease-causing germline mutations are frequent in patients whose tumors stain negative for PMS2 protein, but paralogous genes obscure mutation detection and interpretation. Cancer Res 2004; 64:4721-7.
12. Truninger K, Menigatti M, Luz J, et al. Immunohistochemical analysis reveals high frequency of PMS2 defects in colorectal cancer. Gastroenterology 2005; 128:1160-71.
13. Gallinger S, Aronson M, Shayan K, et al. Gastrointestinal cancers and neurofibro-matosis type 1 features in children with a germline homozygous MLH1 mutation. Gastroenterology 2004; 126:576-85.
14. Bougeard G, Charbonnier F, Moerman A, et al. Early onset brain tumor and lymphoma in MSH2-deficient children. Am J Hum Genet 2003; 72:213-6.
15. Whiteside D, Mc Leod R, Graham G, et al. A homozygous germ-line mutation in the human MSH2 gene predisposes to hematological malignancy and multiple cafe-au-lait spots. Cancer Res 2002; 62:359-62.
16. Garg K, Leitao MM Jr, Kauff ND, et al. Selection of endometrial carcinomas for DNA mismatch repair protein immunohistochemistry using patient age and tumor morphology enhances detection of mismatch repair abnormalities. Am J Surg Pathol 2009; 33:9 25-33.
17. Hampel H, Frankel W, Panescu J, et al. Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Res 2006; 66:7810-7.
18. Aarnio M, Mecklin JP, Aaltonen LA, et al. Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome. Int J Cancer 1995; 64:430-3.
19. Mecklin JP, Jarvinen HJ. Tumor spectrum in cancer family syndrome (hereditary nonpolyposis colorectal cancer). Cancer 1991; 68:1109-12.
20. Mueller CM, Caporaso N, Greene MH. Familial and genetic risk of transitional cell carcinoma of the urinary tract. Urol Oncol 2008; 26:451-64.
21. Broaddus RR, Lynch PM, Lu KH, et al. Unusual tumors associated with the hereditary nonpolyposis colorectal cancer syndrome. Mod Pathol 2004; 17:981-9.
22. den Bakker MA, Seynaeve C, Kliffen M, et al. Microsatellite instability in a pleo-morphic rhabdomyosarcoma in a patient with hereditary non-polyposis colorectal cancer. Histopathology 2003; 43:297-9.
23. Sijmons R, Hofstra R, Hollema H, et al. Inclusion of malignant fibrous histiocy-toma in the tumour spectrum associated with hereditary non-polyposis colorectal cancer. Genes Chromosomes Cancer 2000; 29:353-5.
24. Kawaguchi K, Oda Y, Takahira T, et al. Microsatellite instability and hMLH1 and hMSH2 expression analysis in soft tissue sarcomas. Oncol Rep 2005; 13:241-6.
25. Lynch HT, Lynch JF, Lynch PM, et al. Hereditary colorectal cancer syndromes: molecular genetics, genetic counseling, diagnosis and management. Fam Cancer 2008; 7:27-39.
26. Watson P, Vasen HF, Mecklin JP, et al. The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. Int J Cancer 2008; 123:444-9.
27. Soravia C, van der Klift H, Brundler MA, et al. Prostate cancer is part of the hereditary non-polyposis colorectal cancer (HNPCC) tumor spectrum. Am J Med Genet A 2003; 121A:159-62.
28. Barnetson RA, Tenesa A, Farrington SM, et al. Identification and survival of car-riers of mutations in DNA mismatch-repair genes in colon cancer. N Engl J Med 2006; 354:2751-63.
29. Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003; 349:247-57.
30. Jover R, Zapater P, Castells A, et al. Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer. Gut 2006; 55:848-55.
31. Fallik D, Borrini F, Boige V, et al. Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer. Cancer Res 2003; 63:5738-44.
32. Jessurun J, Romero-Guadarrama M, Manivel JC. Medullary adenocarcinoma of the colon: clinicopathologic study of 11 cases. Hum Pathol 1999; 30:843-8.
33. Alexander J, Watanabe T, Wu TT, et al. Histopathological identification of colon cancer with microsatellite instability. Am J Pathol 2001; 158:527-35.
34. Gatalica Z, Torlakovic E. Pathology of the hereditary colorectal carcinoma. Fam Cancer 2008; 7:15-26.
35. Mvundura M, Grosse SD, Hampel H, et al. The cost-effectiveness of genetic test-ing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer. Genet Med 2010; 12:93-104.
36. Lindor NM, Mc Master ML, Lindor CJ, et al. Concise handbook of familial cancer susceptibility syndromes-second edition. J Natl Cancer Inst Monogr 2008; 1-93.
37. Balmaña J, Balaguer F, Castellvi-Bel S, et al. Comparison of predictive models, clinical criteria and molecular tumour screening for the identification of patients with Lynch syndrome in a population-based cohort of colorectal cancer patients. J Med Genet 2008; 45:557-63.
38. Balmaña J, Stockwell DH, Steyerberg EW, et al. Prediction of MLH1 and MSH2 mutations in Lynch syndrome. JAMA 2006; 296:1469-78.
39. Chen S, Wang W, Lee S, et al. Prediction of germline mutations and cancer risk in the Lynch syndrome. JAMA 2006; 296:1479-87.
40. Shia J, Klimstra DS, Nafa K, et al. Value of immunohistochemical detection of DNA mismatch repair proteins in predicting germline mutation in hereditary colorectal neoplasms. Am J Surg Pathol 2005; 29:96-104.
41. Shia J. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syn-drome. Part I. The utility of immunohistochemistry. J Mol Diagn 2008; 10:293-300.
42. Zhang L. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part II. The utility of microsatellite instability testing. J Mol Diagn 2008; 10:301-7.
43. Lynch HT, Lynch JF, Lynch PM. Toward a consensus in molecular diagnosis of hereditary nonpolyposis colorectal cancer (Lynch syndrome). J Natl Cancer Inst 2007; 99:261-3.
44. Lagerstedt Robinson K, Liu T, Vandrovcova J, et al. Lynch syndrome (hereditary nonpolyposis colorectal cancer) diagnostics. J Natl Cancer Inst 2007; 99: 291-9.
45. Raevaara TE, Korhonen MK, Lohi H, et al. Functional significance and clinical phenotype of nontruncating mismatch repair variants of MLH1. Gastroenterology 2005; 129:537-49.
46. Salovaara R, Loukola A, Kristo P, et al. Population-based molecular detection of hereditary nonpolyposis colorectal cancer. J Clin Oncol 2000; 18:2193-200.
47. Pinol V, Castells A, Andreu M, et al. Accuracy of revised Bethesda guidelines, mic-rosatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. JAMA 2005; 293:1986-94.
48. Young J, Simms LA, Biden KG, et al. Features of colorectal cancers with high-level microsatellite instability occurring in familial and sporadic settings: parallel pathways of tumorigenesis. Am J Pathol 2001; 159:2107-16.
49. Hitchins MP, Wong JJ, Suthers G, et al. Inheritance of a cancer-associated MLH1 germ-line epimutation. N Engl J Med 2007; 356:697-705.
50. Domingo E, Niessen RC, Oliveira C, et al. BRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes. Oncogene 2005; 24:3995-8.
51. Weisenberger DJ, Siegmund KD, Campan M, et al. CpG island methylator phe-notype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 2006; 38:787-93.
52. Kambara T, Simms LA, Whitehall VL, et al. BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum. Gut 2004; 53:1137-44.
53. Domingo E, Laiho P, Ollikainen M, et al. BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. J Med Genet 2004; 41:664-8.
54. Palomaki GE, Mc Clain MR, Melillo S, et al. EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genet Med 2009; 11:42-65.
55. Jarvinen HJ, Aarnio M, Mustonen H, et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 2000; 118:829-34.
56. Lindor NM, Rabe K, Petersen GM, et al. Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X. JAMA 2005; 293:1979-85.
57. Attard TM, Cuffari C, Tajouri T, et al. Multicenter experience with upper gastro-intestinal polyps in pediatric patients with familial adenomatous polyposis. Am J Gastroenterol 2004; 99:681-6.
58. Stolte M, Vieth M, Ebert MP. High-grade dysplasia in sporadic fundic gland polyps: clinically relevant or not? Eur J Gastroenterol Hepatol 2003; 15:1153-6.
59. Galiatsatos P, Foulkes WD. Familial adenomatous polyposis. Am J Gastroenterol 2006; 101:385-98.
60. Aretz S, Koch A, Uhlhaas S, et al. Should children at risk for familial adenomatous polyposis be screened for hepatoblastoma and children with apparently sporadic hepatoblastoma be screened for APC germline mutations? Pediatr Blood Cancer 2006; 47:811-8.
61. Cetta F, Montalto G, Gori M, et al. Germline mutations of the APC gene in patients with familial adenomatous polyposis-associated thyroid carcinoma: results from a European cooperative study. J Clin Endocrinol Metab 2000; 85:286-92.
62. Tomoda C, Miyauchi A, Uruno T, et al. Cribriform-morular variant of papillary thyroid carcinoma: clue to early detection of familial adenomatous polyposis-associated colon cancer. World J Surg 2004; 28:886-9.
63. Wennstrom J, Pierce ER, Mc Kusick VA. Hereditary benign and malignant lesions of the large bowel. Cancer 1974; 34(suppl):850-7.
64. Laken SJ, Petersen GM, Gruber SB, et al. Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC Nat Genet 1997; 17:79-83.
65. Giardiello FM, Krush AJ, Petersen GM, et al. Phenotypic variability of familial adenomatous polyposis in 11 unrelated families with identical APC gene muta-tion. Gastroenterology 1994; 106:1542-7.
66. Caspari R, Olschwang S, Friedl W, et al. Familial adenomatous polyposis: desmoid tumours and lack of ophthalmic lesions (CHRPE) associated with APC mutations beyond codon 1444. Hum Mol Genet 1995; 4:337-40.
67. Olschwang S, Tiret A, Laurent-Puig P, et al. Restriction of ocular fundus lesions to a specific subgroup of APC mutations in adenomatous polyposis coli patients. Cell 1993; 75:959-68.
68. Saurin JC, Ligneau B, Ponchon T, et al. The influence of mutation site and age on the severity of duodenal polyposis in patients with familial adenomatous polyposis. Gastrointest Endosc 2002; 55:342-7.
69. Locker GY, Kaul K, Weinberg DS, et al. The I1307K APC polymorphism in Ash-kenazi Jews with colorectal cancer: clinical and pathologic features. Cancer Genet Cytogenet 2006; 169:33-8.
70. Zhou XL, Eriksson U, Werelius B, et al. Definition of candidate low risk APC alleles in a Swedish population. Int J Cancer 2004; 110:550-7.
71. Michils G, Tejpar S, Fryns JP, et al. Pathogenic mutations and rare variants of the APC gene identified in 75 Belgian patients with familial adenomatous polyposis by fluorescent enzymatic mutation detection (EMD). Eur J Hum Genet 2002; 10:505-10.
72. Frayling IM, Beck NE, Ilyas M, et al. The APC variants I1307K and E1317Q are associated with colorectal tumors, but not always with a family history. Proc Natl Acad Sci USA 1998; 95:10722-7.
73. Knudsen AL, Bisgaard ML, Bulow S. Attenuated familial adenomatous polyposis (AFAP). A review of the literature. Fam Cancer 2003; 2:43-55.
74. Hernegger GS, Moore HG, Guillem JG. Attenuated familial adenomatous pol-yposis: an evolving and poorly understood entity. Dis Colon Rectum 2002; 45:127-34, discussion 34-6.
75. Spirio LN, Samowitz W, Robertson J, et al. Alleles of APC modulate the frequency and classes of mutations that lead to colon polyps. Nat Genet 1998; 20:385-8.
76. Neklason DW, Stevens J, Boucher KM, et al. American founder mutation for at-tenuated familial adenomatous polyposis. Clin Gastroenterol Hepatol 2008; 6:46-52.
77. Aretz S, Uhlhaas S, Goergens H, et al. MUTYH-associated polyposis: 70 of 71 patients with biallelic mutations present with an attenuated or atypical phenotype. Int J Cancer 2006; 119:807-14.
78. Sieber OM, Lipton L, Crabtree M, et al. Multiple colorectal adenomas, classic adenomatous polyposis, and germ-line mutations in MYH. N Engl J Med 2003; 348:791-9.
79. Al-Tassan N, Chmiel NH, Maynard J, et al. Inherited variants of MYH associated with somatic G:C- TA mutations in colorectal tumors. Nat Genet 2002; 30:227-32.
80. Matsumoto T, Esaki M, Fujisawa R, et al. Chromoendoscopy, narrow-band imaging colonoscopy, and autofluorescence colonoscopy for detection of diminutive colorectal neoplasia in familial adenomatous polyposis. Dis Colon Rectum 2009; 52:1160-5.
81. Gorlin RJ, Cohen MM Jr, Condon LM, et al. Bannayan-Riley-Ruvalcaba syndrome. Am J Med Genet 1992; 44:307-14.
82. Dachman AH, Buck JL, Burke AP, et al. Cronkhite-Canada syndrome: radiologic features. Gastrointest Radiol 1989; 14:285-90.
83. Lindor NM, Greene MH. The concise handbook of family cancer syndromes. Mayo Familial Cancer Program. J Natl Cancer Inst 1998; 90:1039-71.
84. Finan MC, Ray MK. Gastrointestinal polyposis syndromes. Dermatol Clin 1989; 7:419-34.
85. Tomlinson IP, Houlston RS. Peutz-Jeghers syndrome. J Med Genet 1997; 34:1007-11.
86. Jeghers H, Mc Kusick VA, Katz KH. Generalized intestinal polyposis and melanin spots of the oral mucosa, lips and digits; a syndrome of diagnostic significance. N Engl J Med 1949; 241:1031-6.
87. Wang ZJ, Ellis I, Zauber P, et al. Allelic imbalance at the LKB1 (STK11) locus in tumours from patients with Peutz-Jeghers' syndrome provides evidence for a hamartoma-(adenoma)-carcinoma sequence. J Pathol 1999; 188:9-13.
88. Hearle N, Schumacher V, Menko FH, et al. Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. Clin Cancer Res 2006; 12:3209-15.
89. Young RH, Welch WR, Dickersin GR, et al. Ovarian sex cord tumor with annular tubules: review of 74 cases including 27 with Peutz-Jeghers syndrome and four with adenoma malignum of the cervix. Cancer 1982; 50:1384-402.
90. Giardiello FM, Hamilton SR, Kern SE, et al. Colorectal neoplasia in juvenile polyposis or juvenile polyps. Arch Dis Child 1991; 66:971-5.
91. Jass JR, Williams CB, Bussey HJ, et al. Juvenile polyposis-a precancerous condi-tion. Histopathology 1988; 13:619-30.
92. Sayed MG, Ahmed AF, Ringold JR, et al. Germline SMAD4 or BMPR1A muta-tions and phenotype of juvenile polyposis. Ann Surg Oncol 2002; 9:901-6.
93. Howe JR, Bair JL, Sayed MG, et al. Germline mutations of the gene encoding bone morphogenetic protein receptor 1A in juvenile polyposis. Nat Genet 2001; 28:184-7.
94. Houlston RS, Webb E, Broderick P, et al. Meta-analysis of genome-wide associa-tion data identifies four new susceptibility loci for colorectal cancer. Nat Genet 2008; 40:1426-35.
95. Eng C. Will the real Cowden syndrome please stand up: revised diagnostic criteria. J Med Genet 2000; 37:828-30.
96. Whitelaw SC, Murday VA, Tomlinson IP, et al. Clinical and molecular features of the hereditary mixed polyposis syndrome. Gastroenterology 1 997; 112:327-34.
97. Jaeger EE, Woodford-Richens KL, Lockett M, et al. An ancestral Ashkenazi hap-lotype at the HMPS/CRAC1 locus on 15q13-q14 is associated with hereditary mixed polyposis syndrome. Am J Hum Genet 2003; 72:1261-7.
98. Thomas HJ, Whitelaw SC, Cottrell SE, et al. Genetic mapping of hereditary mixed polyposis syndrome to chromosome 6q. Am J Hum Genet 1996; 58:770-6.
99. Cao X, Eu KW, Kumarasinghe MP, et al. Mapping of hereditary mixed polyposis syndrome (HMPS) to chromosome 10q23 by genomewide high-density single nucleotide polymorphism (SNP) scan and identification of BMPR1A loss of func-tion. J Med Genet 2006; 43:e13.
100. Lichtenstein P, Holm NV, Verkasalo PK, et al. Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000; 343:78-85.
101. Tomlinson IP, Webb E, Carvajal-Carmona L, et al. A genome-wide association study identifies colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3. Nat Genet 2008; 40:623-30.
102. Broderick P, Carvajal-Carmona L, Pittman AM, et al. A genome-wide association study shows that common alleles of SMAD7 influence colorectal cancer risk. Nat Genet 2007; 39:1315-7.
103. Tenesa A, Farrington SM, Prendergast JG, et al. Genome-wide association scan identifies a colorectal cancer susceptibility locus on 11q23 and replicates risk loci at 8q24 and 18q21. Nat Genet 2008; 40:631-7.
104. Zanke BW, Greenwood CM, Rangrej J, et al. Genome-wide association scan identifies a colorectal cancer susceptibility locus on chromosome 8q24. Nat Genet 2007; 39:989-94.
105. Berndt SI, Potter JD, Hazra A, et al. Pooled analysis of genetic variation at chromo-some 8q24 and colorectal neoplasia risk. Hum Mol Genet 2008; 17:2665-72.
106. Tomlinson I, Webb E, Carvajal-Carmona L, et al. A genome-wide association scan of tag SNPs identifies a susceptibility variant for colorectal cancer at 8q24.21. Nat Genet 2007; 39:984-8.
107. Tuupanen S, Turunen M, Lehtonen R, et al. The common colorectal cancer pre-disposition SNP rs6983267 at chromosome 8q24 confers potential to enhanced Wnt signaling. Nat Genet 2009; 41:885-90.
108. Pomerantz MM, Ahmadiyeh N, Jia L, et al. The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer. Nat Genet 2009; 41:882-4.
109. Solé X, Hernández P, de Heredia ML, et al. Genetic and genomic analysis model-ing of germline c-MYC overexpression and cancer susceptibility. BMC Genomics 2008; 9:12.
110. Winawer SJ, Zauber AG, Gerdes H, et al. Risk of colorectal cancer in the families of patients with adenomatous polyps. National Polyp Study Workgroup. N Engl J Med 1996; 334:82-7.
111. Khoury MJ, Mc Bride CM, Schully SD, et al. The Scientific Foundation for personal genomics: recommendations from a National Institutes of Health-Centers for Disease Control and Prevention multidisciplinary workshop. Genet Med 2009; 11:559-67.
112. Offit K. Genomic profiles for disease risk: predictive or premature? JAMA 2008; 299:1353-5.
113. Robson ME, Storm CD, Weitzel J, et al. American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol 2010; 28:893-901.